The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

prazosin     [4-(4-amino-6,7-dimethoxy- quinazolin-2...

Synonyms: Prazocin, Vasoflex, Furazosin, Lentopres, Minipress, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Minipress

 

Psychiatry related information on Minipress

  • Atropine, a central anticholinergic agent, but not methylatropine, a peripheral one, completely suppressed the prazosin effect, which suggests that adrenergic and cholinergic systems act sequentially and not independently to generate cataplexy [5].
  • Subsequent studies showed that the beneficial effects of classical treatments of human narcolepsy (amphetamines and tricyclic antidepressants) are antagonized by prazosin, suggesting that these drugs are active through an indirect alpha-1 stimulation (via an increase of norepinephrine in the synaptic cleft) [5].
  • Both the increases in extracellular DA levels and in locomotor activity were completely blocked by a pretreatment with prazosin, injected either systemically (0.5 mg/kg, i.p.) or locally and bilaterally into the prefrontal cortex (500 pmol/side) [6].
  • The alpha 1-receptor antagonist prazosin (200 micrograms/kg) also prevented the behavioral effect of restraint, whereas the alpha 1-agonist phenylephrine (50 or 100 ng, i.c.v.) decreased exploratory behavior [7].
  • Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study [8].
 

High impact information on Minipress

 

Chemical compound and disease context of Minipress

 

Biological context of Minipress

 

Anatomical context of Minipress

 

Associations of Minipress with other chemical compounds

 

Gene context of Minipress

  • In this study, using [125I]iodoarylazidoprazosin ([125I]IAAP), a photoactive analog of prazosin, we have demonstrated the presence of two nonidentical drug-interaction sites within Pgp [30].
  • P-gp had no effect on the brain transport of prazosin and mitoxantrone at the mouse BBB, but wild-type and P-gp-deficient mouse brains perfused with GF120918 or a high concentration of prazosin showed carrier-mediated effluxes of prazosin and mitoxantrone from the brain that did not involve P-gp [31].
  • Prazosin enhanced the LS-induced increase of AT1A mRNA (P<.05) [32].
  • Prazosin also enhanced the LS-induced increase in AT1B mRNA (P<.05) [32].
  • Furthermore, in crude membrane preparations, neither the basal nor the prazosin-stimulated ( approximately 2-fold) ATPase activities of ABCG2 (N596Q) were affected compared to glycosylated ABCG2 [33].
 

Analytical, diagnostic and therapeutic context of Minipress

References

  1. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. Miller, R.R., Awan, N.A., Maxwell, K.S., Mason, D.T. N. Engl. J. Med. (1977) [Pubmed]
  2. Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension. Schirger, A., Sheps, S.G. JAMA (1977) [Pubmed]
  3. Alpha-blocker therapy of hypertension. An unfulfilled promise. Khoury, A.F., Kaplan, N.M. JAMA (1991) [Pubmed]
  4. Prazosin in the diagnosis and treatment of pheochromocytoma. Wallace, J.M., Gill, D.P. JAMA (1978) [Pubmed]
  5. Role of central alpha-1 adrenoceptors in canine narcolepsy. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., Dement, W.C. J. Clin. Invest. (1988) [Pubmed]
  6. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. Darracq, L., Blanc, G., Glowinski, J., Tassin, J.P. J. Neurosci. (1998) [Pubmed]
  7. Restraint-stress-induced changes in exploratory behavior appear to be mediated by norepinephrine-stimulated release of CRF. Berridge, C.W., Dunn, A.J. J. Neurosci. (1989) [Pubmed]
  8. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Raskind, M.A., Peskind, E.R., Kanter, E.D., Petrie, E.C., Radant, A., Thompson, C.E., Dobie, D.J., Hoff, D., Rein, R.J., Straits-Tröster, K., Thomas, R.G., McFall, M.M. The American journal of psychiatry. (2003) [Pubmed]
  9. Prazosin treatment of ergotamine-induced peripheral ischemia. Cobaugh, D.S. JAMA (1980) [Pubmed]
  10. Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. Sjöblom, M., Jedstedt, G., Flemström, G. J. Clin. Invest. (2001) [Pubmed]
  11. Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy. Eichler, H.G., Ford, G.A., Blaschke, T.F., Swislocki, A., Hoffman, B.B. J. Clin. Invest. (1989) [Pubmed]
  12. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Albillos, A., García-Pagán, J.C., Iborra, J., Bandi, J.C., Cacho, G., Pérez-Paramo, M., Escorsell, A., Calleja, J.L., Escartín, P., Bosch, J. Gastroenterology (1998) [Pubmed]
  13. Combined prazosin and hydralazine in resistant hypertension. Russell, G.I., Swart, S., Bing, R.F., Thurston, H., Swales, J.D. Lancet (1980) [Pubmed]
  14. Pheochromocytoma and prazosin. Nicholson, J.P., Vaughn, E.D., Pickering, T.G., Resnick, L.M., Artusio, J., Kleinert, H.D., Lopez-Overjero, J.A., Laragh, J.H. Ann. Intern. Med. (1983) [Pubmed]
  15. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. Colucci, W.S. Ann. Intern. Med. (1982) [Pubmed]
  16. Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Mettauer, B., Rouleau, J.L., Bichet, D., Kortas, C., Manzini, C., Tremblay, G., Chatterjee, K. Circulation (1986) [Pubmed]
  17. Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. Marshall, A.J., Barritt, D.W., Pocock, J., Heaton, S.T. Lancet (1977) [Pubmed]
  18. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Fu, M.L., Herlitz, H., Wallukat, G., Hilme, E., Hedner, T., Hoebeke, J., Hjalmarson, A. Lancet (1994) [Pubmed]
  19. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Albillos, A., Lledó, J.L., Rossi, I., Pérez-Páramo, M., Tabuenca, M.J., Bañares, R., Iborra, J., Garrido, A., Escartín, P., Bosch, J. Gastroenterology (1995) [Pubmed]
  20. Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. Magorien, R.D., Triffon, D.W., Desch, C.E., Bay, W.H., Unverferth, D.V., Leier, C.V. Ann. Intern. Med. (1981) [Pubmed]
  21. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Colucci, W.S., Williams, G.H., Braunwald, E. Ann. Intern. Med. (1980) [Pubmed]
  22. Role of vascular endothelium in exercise-induced dilation of large epicardial coronary arteries in conscious dogs. Berdeaux, A., Ghaleh, B., Dubois-Randé, J.L., Vigué, B., Drieu La Rochelle, C., Hittinger, L., Giudicelli, J.F. Circulation (1994) [Pubmed]
  23. Interference of calcium entry blockade in vivo with pressor responses to alpha-adrenergic stimulation: effects of two unrelated blockers on responses to both exogenous and endogenously released norepinephrine. Pedrinelli, R., Tarazi, R.C. Circulation (1984) [Pubmed]
  24. Solubilization and purification of the alpha 1-adrenergic receptor using a novel affinity resin. Graham, R.M., Hess, H.J., Homcy, C.J. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  25. Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Brosnan, C.F., Goldmuntz, E.A., Cammer, W., Factor, S.M., Bloom, B.R., Norton, W.T. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  26. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. Smyth, M.J., Pietersz, G.A., McKenzie, I.F. J. Natl. Cancer Inst. (1987) [Pubmed]
  27. Treating familial Mediterranean fever with prazosin hydrochloride. Kataoka, H., Kumagai, H., Hanai, H. Ann. Intern. Med. (1998) [Pubmed]
  28. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Communal, C., Singh, K., Pimentel, D.R., Colucci, W.S. Circulation (1998) [Pubmed]
  29. Effects of deoxycorticosterone/salt hypertension on cell ploidy in rat aortic smooth muscle cells. Chobanian, A.V., Lichtenstein, A.H., Schwartz, J.H., Hanspal, J., Brecher, P. Circulation (1987) [Pubmed]
  30. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M., Ambudkar, S.V. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  31. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cisternino, S., Mercier, C., Bourasset, F., Roux, F., Scherrmann, J.M. Cancer Res. (2004) [Pubmed]
  32. Regulation of type 1 angiotensin II receptor in adrenal gland: role of alpha1-adrenoreceptor. Wang, D.H., Qiu, J., Hu, Z., Du, Y. Hypertension (1997) [Pubmed]
  33. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Diop, N.K., Hrycyna, C.A. Biochemistry (2005) [Pubmed]
  34. Drug therapy. Prazosin. Koch-Weser, J., Graham, R.M., Pettinger, W.A. N. Engl. J. Med. (1979) [Pubmed]
  35. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. Kitakaze, M., Hori, M., Morioka, T., Minamino, T., Takashima, S., Sato, H., Shinozaki, Y., Chujo, M., Mori, H., Inoue, M. J. Clin. Invest. (1994) [Pubmed]
  36. Autoradiographic analysis of alpha 1-noradrenergic receptors in the human brain postmortem. Effect of suicide. Gross-Isseroff, R., Dillon, K.A., Fieldust, S.J., Biegon, A. Arch. Gen. Psychiatry (1990) [Pubmed]
  37. Alpha-adrenergic receptor stimulation during simulated ischemia and reperfusion in canine cardiac Purkinje fibers. Hamra, M., Rosen, M.R. Circulation (1988) [Pubmed]
  38. Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography. Awan, N.A., Miller, R.R., DeMaria, A.N., Maxwell, K.S., Neumann, A., Mason, D.T. Circulation (1977) [Pubmed]
 
WikiGenes - Universities